Exchange: NASDAQ·Updated 06:52 PM EDT
VTRS logo

VTRSViatris Inc

$16.25
$0.30
(1.89%)
Today
Closed $16.18
$0.07
(0.43%)
After Hours
EarningsAug 6
Mkt Cap$18.64B
Vol13.49M
News
all
press releases
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 PR Newswire PITTSBURGH, July 1, 2026 PITTSBURGH, July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced...
PR Newswire
News Placeholder
More News
News Placeholder
Theravance Stock Down 3% After Zymeworks Announces Buyout
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Zacks
News Placeholder
Here's Why Viatris (VTRS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy PR Newswire PITTSBURGH and...
PR Newswire
News Placeholder
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
VTRS vs. DHR: Which Stock Is the Better Value Option?
VTRS vs. DHR: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Are Investors Undervaluing Viatris (VTRS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
News Placeholder
Here's Why You Should Add LXRX Stock to Your Portfolio Now
Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.
Zacks
News Placeholder
Is Amneal a Buy Before Rytary Generic Erosion?
AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.
Zacks
News Placeholder
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.
Zacks
<
1
2
...
>

Advertisement|Remove ads.